Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer

Cancer Research

Volumn 66, Issue 6, 2006, Pages 3114-3119

  Fukumori, Tomoharu ^a   Oka, Natsuo ^a   Takenaka, Yukinori ^b   Nangia Makker, Pratima ^c   Elsamman, Essam ^a   Kasai, Toshinori ^a   Shono, Masayuki ^a   Kanayama, Hiro Omi ^a   Ellerhorst, Julie ^d   Lotan, Reuben ^d   Raz, Avraham ^c  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c WAYNE STATE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CISPLATIN; CYTOCHROME C; ETOPOSIDE; GALECTIN 3; PROTEIN BAD; SERINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CULTURE MEDIUM; DEPOLARIZATION; DOWN REGULATION; DRUG EFFICACY; DRUG RESISTANCE; DRUG RESPONSE; ENZYME RELEASE; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; CASPASE 3; CASPASES; CELL LINE, TUMOR; CELL NUCLEUS; CISPLATIN; CYTOCHROMES C; ENZYME ACTIVATION; ETOPOSIDE; GALECTIN 3; HUMANS; MALE; MITOCHONDRIA; PROSTATIC NEOPLASMS; TRANSFECTION;

EID: 33645507043     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3750     Document Type: Article

References (32)

1. Jemal A, Tiwari RC, Murray T, et al. American Cancer Society. Cancer statistics. CA Cancer J Clin 2004;54:8-29.
2. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-42.
3. Dixon SC, Knopf KB, Figg WD. The control of prostate-specific antigen expression and gene regulation by pharmacological agents. Pharmacol Rev 2001;53:73-91.
4. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins: structure and function of a large family of animal lectins. J Biol Chem 1994;269:20807-10.
5. Barondes SH, Castronovo V, Cooper DN, et al. Galectins: a family of animal β-galactoside-binding lectins (Letter). Cell 1994;76:597-8.
6. Hughes RC. Galectins as modulators of cell adhesion. Biochimie 2001;83:667-76.
7. Perillo NL, Marcus ME, Baum LG. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 1998;76:402-12.
8. Yang RY, Liu FT. Galectins in cell growth and apoptosis. Cell Mol Life Sci 2003;60:267-76.
9. Inohara H, Raz A. Functional evidence that cell surface galectin-3 mediate homotypic cell adhesion. Cancer Res 1995;55:3267-71.
10. Inohara H, Akahani S, Raz A. Galectin-3 stimulates cell proliferation. Exp Cell Res 1998;245:294-302.
11. Nangia-Makker P, Honjo Y, Sarvis R, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 2000;156:899-909.
12. Fukumori T, Takenaka Y, Oka N, et al. Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Res 2004;64:3376-9.
13. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel anti-apoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 1997;57:5272-6.
14. Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 1999;59:4148-54.
15. Lin HM, Moon BK, Yu F, Kim HR. Galectin-3 mediates genistein-induced G(2)/M arrest and inhibits apoptosis. Carcinogenesis 2000;21:1941-5.
16. Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HRC, Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002;277:6852-7.
17. Takenaka Y, Fukumori T, Yoshii T, et al. Nuclear export of phosphorylated galectin-3 regulates its anti-apoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 2004;24:4395-406.
18. Yu F, Finley RL, Jr., Raz A, Kim HRC. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria A role for synexin in galectin-3 translocation. J Biol Chem 2002; 277:15819-27.
19. van den Brule FA, Waltregny D, Liu FT, Castronovo V. Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 2000;89:361-7.
20. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A 1996;93:6737-42.
21. Sanjuan X, Fernandez PL, Castells A, et al. Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology 1997;113:1906-15.
22. Pacis RA, Pilat MJ, Pienta KJ, et al. Decreased galectin-3 expression in prostate cancer. Prostate 2000; 44:118-23.
23. Califice S, Castronovo V, Bracke M, van den Brule F. Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs. tumor promotion of cytoplasmic galectin-3. Oncogene 2004; 23:7527-36.
24. Ellerhorst JA, Stephens LC, Nguyen T, Xu XC. Effects of galectin-3 expression on growth and tumorigenicity of the prostate cancer cell line LNCaP. Prostate 2004;50:64-70.
25. Fukumori T, Takenaka Y, Yoshii T, et al. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res 2003;63:8302-11.
26. Green DR. Apoptotic pathways: the roads to ruin. Cell 1998;94:695-8.
27. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312-6.
28. Enari M, Talanian RV, Wong WW, Nagata S. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 1996;380:723-6.
29. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell 1995;81:495-504.
30. Davidson PJ, Davis MJ, Patterson RJ, Ripoche MA, Poirier F, Wang JL. Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 2002;12:329-37.
31. Desagher S, Martinou JC. Mitochondria as the central control point of apoptosis. Trends Cell Biol 2000;10:369-77.
32. Ellerhorst J, Nguyen T, Cooper DN, Lotan D, Lotan R. Differential expression of endogenous galectin-1 and galectin-3 in human prostate cancer cell lines and effects of overexpressing galectin-1 on cell phenotype. Int J Oncol 1999;14:217-24.